Skip to main content
. 2005 Jan 24;2005(1):CD002738. doi: 10.1002/14651858.CD002738.pub2

Vogt 1976.

Methods Setting: USA, hospital outpatient clinic 
 Length of intervention period: 4 weeks 
 Randomisation: yes, method not stated 
 Allocation concealment: unclear 
 Design: parallel group 
 Masking: double blind 
 Excluded: not stated 
 Withdrawals: stated 
 Baseline characteristics: comparable (but no data to support) 
 Jadad score: 3
Participants 93 adolescents/adults: 33M 60F 
 Age range: 14 to 65 years 
 Inclusion criteria: 
 Patients with reversible airways disease (not further defined) requiring continuous use of inhaled bronchodilators, but not requiring oral steroids 
 15% or greater improvement in FEV1 following inhaled isoproteronol 
 Exclusion criteria: 
 Not stated
Interventions BDP: 100 mcg 2 pfs 4x daily (800mcg/d)
Placebo: 2 pfs 4xdaily
Delivery device: MDI
Outcomes FEV1 
 FVC 
 FEF25t o 75 
 8 am plasma cortisol 
 Extent of symptom relief score 
 Aerosol evaluation score physicians and patients 
 Withdrawal due to asthma exacerbation (number of patients) 
 Oro‐pharyngeal side effects
Notes Reply from author but unable to clarify method use of allocation concealment.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Unclear risk B ‐ Unclear
HHS Vulnerability Disclosure